This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 May 7;135(19):1611-1612.

doi: 10.1182/blood.2020005362.

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Arnon P Kater¹, J Joseph Melenhorst²

Affiliations

PMID: 32379875
DOI: 10.1182/blood.2020005362

Free article

Comment

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Arnon P Kater et al. Blood. 2020.

Free article

. 2020 May 7;135(19):1611-1612.

doi: 10.1182/blood.2020005362.

Authors

Arnon P Kater¹, J Joseph Melenhorst²

Affiliations

¹ Amsterdam University Medical Centers.
² University of Pennsylvania.

PMID: 32379875
DOI: 10.1182/blood.2020005362

No abstract available

PubMed Disclaimer

Comment on

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, Yeung CCS, Sheih A, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Shadman M, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Blood. 2020 May 7;135(19):1650-1660. doi: 10.1182/blood.2019002936. Blood. 2020. PMID: 32076701 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems